524322
KABRADG
Start SIP
Invest Now
Start SIP in KABRADG
Performance
- Low
- ₹33
- High
- ₹35
- 52 Week Low
- ₹11
- 52 Week High
- ₹36
- Open Price₹33
- Previous Close₹33
- Volume130,162
- 50 DMA₹28.82
- 100 DMA₹25.99
- 200 DMA₹21.35
Investment Returns
- Over 1 Month + 20.32%
- Over 3 Month + 55.39%
- Over 6 Month + 67.16%
- Over 1 Year + 219.6%
Smart Investing Starts Here Start SIP with Kabra Drugs for Steady Growth!
Kabra Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 18.6
- PEG Ratio
- 0.1
- Market Cap Cr
- 80
- P/B Ratio
- 3.1
- Average True Range
- 1.87
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 0.86
- RSI
- 70.34
- MFI
- 80.77
Kabra Drugs Financials
Kabra Drugs Technicals
EMA & SMA
Current Price
₹33.75
+
0.46
(1.38%)
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹30.73
- 50 Day
- ₹28.82
- 100 Day
- ₹25.99
- 200 Day
- ₹21.35
Resistance and Support
33.7
- R3 37.10
- R2 35.95
- R1 34.85
- S1 32.60
- S2 31.45
- S3 30.35
Kabra Drugs Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-13 | Quarterly Results | |
| 2025-11-28 | Others | Inter alia, To sign an agreement with MR FRANCHISE to appoint around 200 channel partner throughout the Country for expansion. |
| 2025-11-13 | Quarterly Results | |
| 2025-10-08 | Others | Inter-aliam to consider 1.Approve the final draft of the Share Purchase Agreement (SPA) in relation to the acquisition of AMR PHARMA INDIA PRIVATE LIMITED. 2. Other business matters. |
| 2025-09-02 | Others | Inter-alia, to consider 1. Directors Report and Corporate Governance Report for the financial year 2024 -25. 2. Draft Notice calling the AGM. 3. Other business matters. |
Kabra Drugs F&O
About Kabra Drugs
- NSE Symbol
- KABRADG
- BSE Symbol
- 524322
- Managing Director
- Mr. N Aravind
- ISIN
- INE323K01017
Similar Stocks to Kabra Drugs
Kabra Drugs FAQs
Kabra Drugs share price is ₹33 As on 14 February, 2026 | 12:23
The Market Cap of Kabra Drugs is ₹80 Cr As on 14 February, 2026 | 12:23
The P/E ratio of Kabra Drugs is 18.6 As on 14 February, 2026 | 12:23
The PB ratio of Kabra Drugs is 3.1 As on 14 February, 2026 | 12:23
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.